Drugs for Neglected Diseases initiative (DNDi): A collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases.
February 22nd, 2017Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected patients.
DNDi is working on the following diseases:
- Leishmaniasis
- Sleeping Sickness (human African trypanosomiasis)
- Chagas disease
- Paediatric HIV
- Filarial diseases
- Mycetoma
- Hepatitis C
In 2015, DNDi handed over its Malaria portfolio.
Achievements
Working in partnership with private industry, public institutions, academia and NGOs, DNDi has built the largest ever R&D portfolio for kinetoplastid diseases.
To date, DNDi has successfully delivered, recommended and implemented:
- Two new fixed-dose combinations for Malaria (2007 & 2008) – ASAQ, ASMQ
- Better simpler treatment against Sleeping Sickness (2009) – NECT
- Cheaper more effective treatment in Africa against Visceral Leishmaniasis (VL) (2010) – SSG&PM
- A set of treatments in South Asia for VL (2011)
- A paediatric form of benznidazole for Chagas disease (2011)
- More effective treatment for children who are co-infected with HIV and TB (2016) – Superbooster Therapy